Atea Pharmaceuticals, Inc.

Idenix Pharmaceuticals, Inc.

Centre National De La Recherche Scientifique

Children's Medical Center Corporation

Pharm-eco Laboratories, Inc.

Biothea Pharma, Inc.

Other

Harvard College

Merck Sharp + Dohme Corp.

Universitè De Montpellier

Université Montpellier 2 Sciences Et Techniques

Nuchem Pharmaceuticals Inc.

Ion Pharmaceuticals, Inc.

Novartis Ag

Johnson Matthey Pharmaceutical Materials, Inc.

Adel M Moussa

Jean-Pierre Sommadossi

Benjamin Alexander Mayes

Alistair James Stewart

Minghua Sun

Richard John Lombardy

Cyril B Dousson

Yesh P Sachdeva

Jose Alberto Halperin

Ying-Duo Gao

David Dukhan

Carlo Brugnara

John J Clifford

Heather N Taft

Eugene W Kelleher

Reem M Haidar

Gilles J Gosselin

Francois-Rene Alexandre

Richard Storer

Christophe Parsy

Claire Pierra

Emile M Bellott

Dominique Surleraux

Salah A Zahr

Mark Froimowitz

Jurjus Jurayj

Peter Emmanuel Maligres

Yong-Li Zhong

Kevin Campos

Richard L Gabriel

Artis Klapars

Houcine Rahali

Gilles Gosselin

Rudolf Fluckiger

David A Swanson

Reem M Haider

Emile M Bellot, Jr

Falguni M Kher

Jing Yang Wang

Michael H Zeldin

Luning Han

Edward Bridges

Xiao-Jian Zhou

Keith M Pietropaolo

Marino Artico

Bryon Ladd Simmons

Paolo LaColla

Guillaume Brandt

Alan Michael Hyde

Frank Walter Waligora

Weiheng Wang

Steven Mark Silverman

Mike H O'Neill

Jean-Francois Griffon

Changhua Liu

Narayan Chaudhuri

Kenneth Baker

HaeSuk Suh

Heather Taft

Kara Van Valkenburg

Jean-François Griffon

Alistar James Stewart

Sharon Fitzhenry

Brittany La

Xiaohong Sheng

Romano Silvestri

Elodie Rosinovsky

Christophe Claude Parsy

Jingyang Wang

Francois-René Alexandre

Frank Waligora

A synergistic pharmaceutical combination of Compound 1 or a pharmaceutically acceptable salt thereof (e.g., Compound 1-A) and Compound 2 or a pharmaceutically acceptable salt thereof, as well as its uses to treat hepatitis C or a condition related to hepatitis C, as well as methods for the manufacture of the pharmaceutical combination:

Advantageous anti-HCV combination therapy

The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

Highly active compounds against COVID-19

Described herein are epinephrine salts, specifically the epinephrine malonate salt; the epinephrine malonate salt in crystalline form; a pharmaceutical composition comprising epinephrine malonate; a sublingual or buccal pharmaceutical composition comprising epinephrine malonate in crystalline form; and a method for treating a patient comprising administering a pharmaceutical composition of epinephrine malonate in crystalline form.

Crystalline epinephrine malonate salt

A compound of the structure: or a pharmaceutically acceptable salt or composition thereof for the treatment of a host infected with or exposed to an HCV virus or other disorders more fully described herein.

β-D-2'-deoxy-2′-α-fluoro-2′-β-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

A hemi-sulfate salt of the structure: to treat a host infected with hepatitis C, as well as pharmaceutical compositions and dosage forms, including solid dosage forms, thereof.

Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus

The use of described compounds or pharmaceutically acceptable salts or compositions thereof for the treatment of a host infected with an RNA virus other than HCV, or other disorder more fully described herein.

2′-substituted-N-substituted purine nucleotides for RNA virus treatment

The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.

A pharmaceutical composition that includes a compound of the structure: to treat an HCV infected patient with cirrhosis, and uses thereof.

Treatment of HCV infected patients with cirrhosis

2'-substituted-N6-substituted purine nucleotides for RNA virus treatment

Nucleotide hemi-sulfate salt for the treatment of hepatitis C virus

Growing community of inventors

Burlington, MA, United States of America

Adel M Moussa